Home > Healthcare & Medical Devices > Tubeless Insulin Pump Market

Tubeless Insulin Pump Market Size By Component (Pod/Patch, Remote), By Distribution Channel (Hospitals, Pharmacies, E-commerce), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

  • Report ID: GMI2032
  • Base Year: 2020
  • Report Format: PDF

Industry Trends

Tubeless Insulin Pump Market size exceeded USD 2.1 billion in 2020 and is anticipated to grow at a CAGR of 21.5% between 2021 and 2027. The development of minimally invasive and innovative diabetes management products is expected to significantly drive the overall market growth. Along with product development, the rising geriatric population contributing to disease burden, preference towards remote monitoring devices, and minimized complications will propel the tubeless insulin pump demand.
 

Tubeless Insulin Pump Market Overview

Get more details on this report - Request Free Sample PDF
 

The focus of companies on the introduction of user-friendly and convenient insulin delivery devices is projected to boost tubeless insulin pump market adoption in the coming years. The growing prevalence of diabetes and technological advancements in insulin delivery to stimulate the industry growth. Diabetes is amongst the largest public health concerns, inflicting significant mortalities and socio-economic impact.

 

However, high costs associated with the long-term use of tubeless insulin pump restrict product acceptance, thereby hampering the tubeless insulin pump market expansion. Inadequate reimbursement in certain countries affects its affordability to patients. New insulins are retailed at relatively high prices in comparison with previously available products. Increased prices are due to the use of new manufacturing techniques and the cost associated with development. Diabetic patients require more than one insulin vial per month that adds to the overall cost of the disease management. As diabetes require long-term medications, it significantly contributes to the economic burden of patients.

 

The COVID-19 arose as an unprecedented public health concern across the globe and has positively impacted the tubeless insulin pump market progression. Diabetic patients suffering from type 1 diabetes (T1D) are more vulnerable and at a high risk of COVID-19. The use of wearable diabetes devices comprising tubeless insulin pump in hospitals has increased significantly during this pandemic. As per the American Diabetes Association (ADA), as part of the management of type 1 diabetes (T1D) in a patient with coronavirus disease, the use of diabetes technology comprising tubeless insulin pump is recommended to improve glycemic control. This pandemic has influenced the usage of tubeless insulin pump in-home care owing to less availability of hospital beds. Due to COVID-19, countries across the world have rapidly arranged services to ensure suitable diabetes care during the pandemic.

 

Growing prevalence of obesity to augment the tubeless insulin pump market value

Obesity is a major risk factor contributing to the higher prevalence of diabetes, thus benefits the demand for diabetes management devices comprising tubeless insulin pump. Obesity leads to increased levels of inflammation and fatty acids that result in insulin resistance causing the risk of type 2 diabetes. Further, it also contributes to cardiometabolic complications and dyslipidemia in patients with type 1 diabetes. According to the Centers for Disease Control and Prevention, the prevalence of obesity was around 42.4% in 2017-2018 in the U.S. Increasing the obese population in such developed nations with high spending ability on advanced treatments propels the industry expansion.
 

Moreover, according to the World Health Organization, nearly 39% of adults aged 18 years and over were overweight and 13% were obese in 2016. Among such obese individuals, the amount of nonesterified fatty acids, pro-inflammatory markers, glycerol, cytokines, and hormones along with other substances is comparatively higher that is responsible for the development of insulin resistance. In addition, changing lifestyle, overeating, physical inactivity, and some psychological factors contribute to the incidence of obesity, thereby fostering the tubeless insulin pump market size. Therefore, a higher prevalence of obesity responsible for the increased incidence of diabetes will benefit the tubeless insulin pump adoption.
 

Technological advancements in pod/patch component will stimulate the market demand

Pod/patch segment dominated more than 60% of the tubeless insulin pump market share in 2020 and was valued at around USD 1.27 billion in 2020 led by the increasing product acceptance due to convenience in insulin delivery without affecting daily activities. Presently, the pod is designed with an embedded algorithm to adjust insulin delivery automatically as per customized glucose target according to the CGM trend and value. Additionally, portability, connectivity, and ease in insulin administration associated with the use of pod will benefit the product demand. Small size and computerization of device enables on-time insulin delivery with continuous glucose monitoring systems. Further, developments in functionality and product design will favour tubeless insulin pump demand in the coming years.
 

Expanding network of pharmacies to enhance the tubeless insulin pump market revenue

Tubeless Insulin Pump Market Size

Get more details on this report - Request Free Sample PDF

 

The pharmacies segment captured 25% of the market share in 2020 driven by the expanding network and increasing product availability in pharmacies. The presence of pharmacies across rural areas and its easy accessibility to the broader population will impel product distribution. Moreover, government efforts to improve healthcare access in developing countries further expands the existing network of pharmacies, thus offering growth opportunities to the segment. The companies are focusing on expanding product accessibility to patients that will result in increasing product availability across pharmacies. As pharmacies are easily accessible at nearby locations across middle as well as low-income nations, the market leaders are focusing on pushing products through these channels that will augment the industry value.
 

Rising awareness in the North America region to curb the diabetes burden will promote the regional growth

Global Tubeless Insulin Pump Market

Get more details on this report - Request Free Sample PDF

 

U.S. tubeless insulin pump market is slated reach over USD 4.46 billion by 2027 owing to multiple factors such as increasing product approvals for advanced devices, growing number of diabetic patients, etc. Strong presence of leading manufacturers focusing on securing approvals and insurance coverage for their products to enhance affordability will majorly accelerate the U.S. market growth. Improving reimbursement scenario in the U.S. increases the product affordability for the American population. Furthermore, increasing healthcare expenditure to diabetes, high spending ability on disease management, and awareness regarding the advent of new technologies are expected to boost the regional growth during the forecast timeline.
 

Strategic initiatives implemented by prominent players to foster the industry revenue

Some of the major companies operating in the tubeless insulin pump market are Insulet Corporation, Medtronic, Tandem Diabetes Care, and F. Hoffman La-Roche among others.   These leaders focus on strategic partnerships, new product launch & commercialization for market expansion. Additionally, these market participants are investing in research and development activities that allow them to garner maximum revenue share.
 

Recent industry developments:

  • In August 2021, Insulet Corporation announced FDA approval for using Eli Lilly’s Lyumjev injection with Insulet’s Omnipod Insulin Management System and Omnipod DASH Insulin Management System. This FDA approval will help the company to bolstered its market presence and offer more clinical choices for diabetes patients to manage their glucose levels. 
     
  • In September 2020, Medtronic announced FDA approval for MiniMed 770G. It is an insulin pump system that can connect with smartphone. This approval helped the company strengthened its business position and expanded insulin pump portfolio.
          

Tubeless insulin pump market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Component 2016 - 2027 (USD Million)

  • Pod/Patch
  • Remote
  • Others

Market, By Distribution Channel, 2016 - 2027 (USD Million)

  • Hospitals
  • Pharmacies
  • E-commerce
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea 
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
       
Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Tubeless insulin pump market size had exceeded USD 2.1 billion in 2020 and will witness a CAGR of 21.5% through 2027 with the development of minimally invasive and innovative diabetes management products.

Some of the major tubeless insulin pump market players are Insulet Corporation, Medtronic, Tandem Diabetes Care, and F. Hoffman La-Roche among others.

Pod/patch tubeless insulin pump market was valued at around USD 1.27 billion in 2020 owing to the convenience offered by these pumps in insulin delivery without affecting daily activities.

U.S. tubeless insulin pump market size will reach over USD 4.46 billion by 2027 owing to the rising product approvals for advanced devices, growing prevalence of diabetes, and strong presence of leading manufacturers in the country.

Pharmacies distribution channel had captured 25% share in 2020 owing to the expanding network and increasing product availability.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Published Date: Oct 2021
  • Companies covered: 12
  • Tables & Figures: 133
  • Countries covered: 16
  • Pages: 134

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount